Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer

Authors

Institutions

Publication Details

Journal
Journal for ImmunoTherapy of Cancer
Published
2026-03-01
DOI
https://doi.org/10.1136/jitc-2025-014365
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer

Shana Y. Trostel, Roshan L. Shrestha, John M. Fenimore, Nahoko Sato et al.
Journal for ImmunoTherapy of Cancer
Prostate Cancer Treatment and Research
article

Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer

Shana Y. Trostel, Roshan L. Shrestha, John M. Fenimore, Nahoko Sato, William L. Dahut, Nicholas T. Terrigino, John R. Bright, Clara C. Y. Seo, Adam G. Sowalsky, Lisa M. Cordes, Meghali Goswami, Ravi Amrit Madan, Anna Baj, Fatima Karzai, Chennan Li, Sunmin Lee, Jeanny B. Aragon-Ching, Kathleen Calzone, Shraddha Rastogi, James L Gulley, S Thomas Hennigan, Jeffrey Schlom, Yi Liu, Min-Jung Lee, Renee N Donahue, William D Figg, Isaiah M King, Jung-Min Lee
article en

Abstract

No abstract available for this paper.
Journal for ImmunoTherapy of CancerVol. 14(3)
Virginia Cancer Institute (US), National Cancer Institute (US)
Good health and well-being
Openalex Percentile: Top 9%
Prostate Cancer Treatment and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.